The MTDDP comprises a multidisciplinary group of scientists who are committed to making basic laboratory observations about therapeutic targets and potential strategies, exploring their feasibility in preclinical models, and translating the most promising approaches and molecules into the clinical setting.
The scientific objective of the MTDDP is to enhance cancer treatment by fostering a highly interactive and vertically integrated drug discovery and development program in which information moves bi-directionally between basic and clinical scientists. To achieve this objective, members of the MTDDP perform mechanistic and innovative studies on novel agents, new targets, and novel drug delivery systems with the goals of identifying new anticancer agents, understanding the mechanism(s) of action of new and existing anticancer drugs, and optimizing schedules and doses of antineoplastic drugs.
Central to the MTDDP's mission is the acquisition of sufficient laboratory derived data to develop more efficacious clinical therapies against human solid tumors and hematologic malignancies. The MTDDP has focused on establishing both a strong basic science foundation to support the development of small molecule, anti cancer agents and novel therapeutic approaches against malignancy, and a robust capability to perform clinical trials with the most promising agents and approaches.